Matthew C. Kapusta Sells 39,169 Shares of Uniqure NV (QURE) Stock

Uniqure NV (NASDAQ:QURE) CEO Matthew C. Kapusta sold 39,169 shares of the business’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $21.72, for a total value of $850,750.68. Following the completion of the sale, the chief executive officer now directly owns 439,764 shares in the company, valued at approximately $9,551,674.08. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Matthew C. Kapusta also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Thursday, January 4th, Matthew C. Kapusta sold 21,690 shares of Uniqure stock. The shares were sold at an average price of $19.87, for a total value of $430,980.30.

Shares of Uniqure stock traded down $0.79 on Monday, reaching $20.80. The company’s stock had a trading volume of 389,982 shares, compared to its average volume of 400,066. The company has a current ratio of 8.46, a quick ratio of 8.46 and a debt-to-equity ratio of 0.22. Uniqure NV has a 52-week low of $4.72 and a 52-week high of $27.19. The company has a market cap of $684.06, a P/E ratio of -7.06 and a beta of 0.09.

QURE has been the topic of several recent analyst reports. HC Wainwright set a $35.00 price target on Uniqure and gave the company a “buy” rating in a research note on Tuesday, February 20th. Zacks Investment Research lowered Uniqure from a “hold” rating to a “sell” rating in a research note on Saturday, February 24th. BidaskClub raised Uniqure from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. ValuEngine raised Uniqure from a “sell” rating to a “hold” rating in a research note on Tuesday, December 26th. Finally, Janney Montgomery Scott initiated coverage on Uniqure in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $20.75.

A number of institutional investors and hedge funds have recently modified their holdings of QURE. OxFORD Asset Management LLP bought a new position in Uniqure in the 3rd quarter valued at $399,000. Mangrove Partners raised its position in shares of Uniqure by 167.4% during the third quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock worth $1,024,000 after acquiring an additional 66,763 shares during the last quarter. First Manhattan Co. bought a new stake in shares of Uniqure during the fourth quarter worth $1,371,000. SG Americas Securities LLC bought a new stake in shares of Uniqure during the fourth quarter worth $119,000. Finally, Victory Capital Management Inc. bought a new stake in shares of Uniqure during the fourth quarter worth $1,298,000. Hedge funds and other institutional investors own 43.98% of the company’s stock.

WARNING: “Matthew C. Kapusta Sells 39,169 Shares of Uniqure NV (QURE) Stock” was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thestockobserver.com/2018/03/19/matthew-c-kapusta-sells-39169-shares-of-uniqure-nv-qure-stock.html.

About Uniqure

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease.

Insider Buying and Selling by Quarter for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply